The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (<i>ALK</i>) with tyrosine kinase inhibitors (TKIs), is challenged by the emergence of therapeutic resistance. This evidence concerns the gene ALK and non-small cell lung carcinoma.